4.2 Article

Rooted in risk: genetic predisposition for low-density lipoprotein cholesterol level associates with diminished low-density lipoprotein cholesterol response to statin treatment

Journal

PHARMACOGENOMICS
Volume 17, Issue 15, Pages 1621-1628

Publisher

FUTURE MEDICINE LTD
DOI: 10.2217/pgs-2016-0091

Keywords

MR-Egger; pharmacogenetics; statin therapy

Funding

  1. Steering Committee of the Yale Open Data Access Project by Johnson Johnson
  2. JUPITER from AstraZeneca
  3. Netherlands Heart Foundation [2001 D 032]
  4. Medical Research Council [MR/K006584/1] Funding Source: researchfish

Ask authors/readers for more resources

Aims: To utilize previously reported lead SNPs for low-density lipoprotein cholesterol (LDL-c) levels to find additional loci of importance to statin response, and examine whether genetic predisposition to LDL-c levels associates with differential statin response. Methods: We investigated effects on statin response of 59 LDL-c SNPs, by combining summary level statistics from the Global Lipids Genetics and Genomic Investigation of Statin Therapy consortia. Results: Lead SNPs for APOE, SORT1 and NPC1L1 were associated with a decreased LDL-c response to statin treatment, as was overall genetic predisposition for increased LDL-c levels as quantified with 59 SNPs, with a 5.4% smaller statin response per standard deviation increase in genetically raised LDL-c levels. Conclusion: Genetic predisposition for increased LDL-c level may decrease efficacy of statin therapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available